Association of malnutrition with geriatric assessment impairments and health‐related quality of life among older adults with gastrointestinal malignancies
Gastric cancer patients over age 60 face a high risk of malnutrition, which lowers their quality of life and leads to a... Read More
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
The FDA granted fast-track designation to Leap Therapeutics’ DKN-01, which blocks the DKK1 protein found in abundance in some gastric tumors.
Enhertu now approved in Japan for gastric cancer
Enhertu from Daiichi-Sankyo is now approved in Japan for the treatment of HER2-positive gastric cancer.
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Leap Therapeutics and BeiGene have started dosing patients in a trial combining an anti-PD-1 antibody with the novel targeted drug DKN-01 in... Read More
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
In a recent trial, Keytruda was found to be as effective as chemotherapy in previously untreated gastric cancer patients, but it caused... Read More
Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer
Laparoscopic surgery was equally effective as open surgery in gastric cancer patients in extending relapse-free survival periods, a recent study found.
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma
Combining Cyramza with IMFINZI® (durvalumab) was safe and effective in a small trial that included gastric cancer patients.
Pieris and Lilly enter into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 with Ramucirumab and Paclitaxel in Gastric Cancer
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive gastric cancer.
First US clinical trial testing efficacy of delivering aerosolized chemotherapy
City of Hope is recruiting patients with gastric cancer for a trial of a chemotherapy spray that can be delivered straight to... Read More
Immune Protein IL-17A Responsible for Lethal Side Effects of Gastric Cancer
Researchers in Japan discovered that the pro-inflammatory cytokine IL-17A plays a role in promoting peritoneal spread in gastric cancer, and they suggested... Read More
